血清PGRN蛋白与痴呆认知相关性研究
发布时间：2018-08-26 07:28
【摘要】：[目的]随着我国老年人口数目的不断增多,阿尔茨海默病(Alzheimer's disease,AD)作为一种起病隐匿的中枢神经退行性疾病,目前已成为全球研究的热点。阿尔茨海默病是老年痴呆中的一种常见类型,它以渐进性记忆衰退、认知功能下降、精神、行为反常为主要临床表现,对老年人的日常生活带来了极其严重的损害,所以早期识别、早期诊断及干预对于痴呆患者尤为重要。近年来有相关证明,颗粒蛋白前体(Progranulin,PGRN)与额颞叶痴呆、阿尔茨海默病、乳腺癌、多发性硬化、系统性红斑狼疮等多种疾病相关,但该蛋白对于人阿尔茨海默病的影响却少有研究,根据以往研究,PGRN的某些机制与阿尔茨海默病和血管性痴呆的发病相关,且PGRN能穿过血脑屏障,在外周血中表达,研究发现PGRN可能参与AD和VD的致病,因此我们在几种类型的痴呆患者中测量了血清PGRN蛋白的浓度,并测评了 MMSE等与认知相关的量表以探究二者之间的关联性。[方法]选取11例阿尔茨海默病患者、20例血管性痴呆患者、24例混合性痴呆患者及55例年龄、性别相匹配的健康患者,采用酶联免疫吸附技术(enzyme-linked immunosorbent assay,ELISA)测定其血清PGRN蛋白浓度水平,通过MMSE(Mini-mental state examination)、ADAS-cog(Alzheimer's disease assessment scale cognitive section)、日常生活能力(Activity of daily living,ADL)等量表的评定对痴呆患者记忆及认知进行评估,使用SPSS22.0(Statistical Package For Social Science,SPSS)软件包对一般统计资料及所有量表资料进行统计分析,采用方差分析比较四组量表评分及四组血清PGRN蛋白浓度的差异,事后检验采用LSD-t法进行两两进一步比较。对四组的血清PGRN蛋白浓度与ADAS评分、ADL评分及MMSE评分各细则,对于符合正态分布的数据采用pearson相关分析,对不符合正态分布的数据采用spearson进行分析。以p0.05认为差异有统计学意义。[结果]1.研究组与对照组之间MMSE量表、ADL量表、ADAS-cog量表评分、血清PGRN蛋白浓度两两比较,研究组与对照组量表总分(P0.05),两两比较后发现研究组各组间量表总分:P均大于0.05,研究组与对照组量表总分:P值均小于0.05。AD组血清PGRN蛋白浓度(13.69±1.99)ng/ml,VD组血清PGRN蛋白浓度(19.39±1.34)ng/ml,MD组血清PGRN蛋白浓度(18.38±1.05)ng/ml,对照组血清 PGRN 蛋白浓度(20.39±1.69)ng/ml。2.研究组与对照组血清PGRN蛋白浓度比较(F = 59.36,P0.01),差异有统计学意义,进一步进行两两比较,[(MD组)vs(AD组)](P0.05),[(VD组)vs(MD组)](P0.05),[(对照组)vs(VD组)](P0.05)。3.研究组血清PGRN蛋白与MMSE、ADL、ADAS-cog量表各分组评分及总分比较,P均大于0.05,进一步探讨各个研究组血清PGRN蛋白浓度与量表分组及总分之间的相关性,各项P均0.05,但AD组MMSE量表中即刻回忆一项(P0.05,r=0.037),差异有统计学意义。[结论]1.研究各组间认知量表评分无明显相关,研究组量表评分及血清PGRN蛋白浓度显著低于对照组。2.血清PGRN浓度:AD组MD组VD组对照组,血清PGRN蛋白可能参与AD、VD、MD发病。3.研究组血清PGRN蛋白与MMSE、ADL、ADAS-cog量表评分无关,但可能与AD患者中即刻回忆一项有关。
[Abstract]:[Objective] Alzheimer's disease (AD), as a latent central neurodegenerative disease, has become a global research hotspot with the increasing number of the elderly population in China. Alzheimer's disease is a common type of Alzheimer's disease. Early identification, early diagnosis and intervention are particularly important for dementia patients. Progranulin (PGRN) has been shown to be associated with frontotemporal dementia, Alzheimer's disease, breast cancer, multiple sclerosis, and systemic disease in recent years. Lupus erythematosus and other diseases are related, but the effect of PGRN on human Alzheimer's disease is seldom studied. According to previous studies, some mechanisms of PGRN are related to the pathogenesis of Alzheimer's disease and vascular dementia, and PGRN can be expressed in peripheral blood through the blood-brain barrier. Serum PGRN levels were measured in several types of dementia patients, and MMSE and other cognitive related scales were evaluated to explore the correlation between the two. Serum PGRN levels were measured by enzyme-linked immunosorbent assay (ELISA). Memory and activity of daily living (ADL) were assessed by MMSE (Mini-mental state examination), ADAS-cog (Alzheimer's disease assessment scale cognitive section) and other scale s. Cognition was assessed. Statistical Package for Social Science (SPSS) software package was used to analyze the general statistical data and all the scale data. Variance analysis was used to compare the differences between the four scale scores and the serum PGRN protein concentration of the four groups. LSD-t method was used to further compare the four groups. The serum PGRN protein concentration and ADAS score, ADL score and MMSE score were analyzed by Pearson correlation analysis for the data conforming to normal distribution and spearson analysis for the data not conforming to normal distribution. Compared with the control group, the total score of each group was higher than 0.05, and the total score of the study group and the control group was lower than 0.05. The concentration of serum PGRN protein in AD group was 13.69 (+ 1.99) ng/ml, and the concentration of serum PGRN protein in VD group was 19.39 (+ 1.34) ng/ml, MD group was lower than that in MD group. Serum PGRN protein concentration (18.38 (1.05) ng/ml, control group serum PGRN protein concentration (20.39 (1.69) ng/ml.2. Study group and control group serum PGRN protein concentration (F = 59.36, P 0.01), the difference was statistically significant, further two comparisons, [(MD group) vs (AD group)] (P 0.05), [(VD group) vs (MD group)] (P 0.05), [(control group) vs (VD group)] (P 0.05)] (P 0.3. The serum PGRN protein and MMSE, ADL, ADAS-cog scales were more than 0.05 in each group, P was greater than 0.05, further explore the correlation between the serum PGRN protein concentration and the scale grouping and total score, P was 0.05, but the AD group MMSE scale immediately recall one item (P 0.05, r = 0.037), the difference was statistically significant. [Conclusion]1. There was no significant correlation between cognitive scale scores and serum PGRN concentration. 2. Serum PGRN concentration: AD group MD group VD control group, serum PGRN protein may participate in AD, VD, MD onset. 3. Study group serum PGRN protein and MMSE, ADL, ADAS-cog scale score is not related, but may be related to AD patients in the moment. Recall a related story.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R749.16
本文编号：2204156
[Abstract]:[Objective] Alzheimer's disease (AD), as a latent central neurodegenerative disease, has become a global research hotspot with the increasing number of the elderly population in China. Alzheimer's disease is a common type of Alzheimer's disease. Early identification, early diagnosis and intervention are particularly important for dementia patients. Progranulin (PGRN) has been shown to be associated with frontotemporal dementia, Alzheimer's disease, breast cancer, multiple sclerosis, and systemic disease in recent years. Lupus erythematosus and other diseases are related, but the effect of PGRN on human Alzheimer's disease is seldom studied. According to previous studies, some mechanisms of PGRN are related to the pathogenesis of Alzheimer's disease and vascular dementia, and PGRN can be expressed in peripheral blood through the blood-brain barrier. Serum PGRN levels were measured in several types of dementia patients, and MMSE and other cognitive related scales were evaluated to explore the correlation between the two. Serum PGRN levels were measured by enzyme-linked immunosorbent assay (ELISA). Memory and activity of daily living (ADL) were assessed by MMSE (Mini-mental state examination), ADAS-cog (Alzheimer's disease assessment scale cognitive section) and other scale s. Cognition was assessed. Statistical Package for Social Science (SPSS) software package was used to analyze the general statistical data and all the scale data. Variance analysis was used to compare the differences between the four scale scores and the serum PGRN protein concentration of the four groups. LSD-t method was used to further compare the four groups. The serum PGRN protein concentration and ADAS score, ADL score and MMSE score were analyzed by Pearson correlation analysis for the data conforming to normal distribution and spearson analysis for the data not conforming to normal distribution. Compared with the control group, the total score of each group was higher than 0.05, and the total score of the study group and the control group was lower than 0.05. The concentration of serum PGRN protein in AD group was 13.69 (+ 1.99) ng/ml, and the concentration of serum PGRN protein in VD group was 19.39 (+ 1.34) ng/ml, MD group was lower than that in MD group. Serum PGRN protein concentration (18.38 (1.05) ng/ml, control group serum PGRN protein concentration (20.39 (1.69) ng/ml.2. Study group and control group serum PGRN protein concentration (F = 59.36, P 0.01), the difference was statistically significant, further two comparisons, [(MD group) vs (AD group)] (P 0.05), [(VD group) vs (MD group)] (P 0.05), [(control group) vs (VD group)] (P 0.05)] (P 0.3. The serum PGRN protein and MMSE, ADL, ADAS-cog scales were more than 0.05 in each group, P was greater than 0.05, further explore the correlation between the serum PGRN protein concentration and the scale grouping and total score, P was 0.05, but the AD group MMSE scale immediately recall one item (P 0.05, r = 0.037), the difference was statistically significant. [Conclusion]1. There was no significant correlation between cognitive scale scores and serum PGRN concentration. 2. Serum PGRN concentration: AD group MD group VD control group, serum PGRN protein may participate in AD, VD, MD onset. 3. Study group serum PGRN protein and MMSE, ADL, ADAS-cog scale score is not related, but may be related to AD patients in the moment. Recall a related story.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R749.16
【参考文献】
相关期刊论文 前10条
1 闫涛;;治疗阿尔茨海默病的药物研究进展[J];天津药学;2016年03期
2 单体臻;王新;王海峰;庄珊;邢成名;;血清MMP-2、MMP-9水平与阿尔茨海默病及轻度认知障碍关系的临床研究[J];中国医刊;2016年06期
3 齐倩倩;刘志娟;吕佩源;;血管性认知功能障碍危险因素的研究进展[J];疑难病杂志;2015年12期
4 王菲;;血管性痴呆的分子机制及治疗学研究进展[J];中国神经精神疾病杂志;2014年05期
5 Zhichun Chen;Chunjiu Zhong;;Oxidative stress in Alzheimer's disease[J];Neuroscience Bulletin;2014年02期
6 栾冰;许微微;王靳君;;老年痴呆症发病机制及其药物治疗[J];中国药物经济学;2013年06期
7 曾瀛;徐丽君;唐震宇;邓丽影;;阿尔茨海默病患者尿液中相关的神经丝蛋白的诊断价值[J];中国老年学杂志;2013年13期
8 卢英红;吕兰海;罗利;李博斐;徐杰;;短暂性脑缺血再灌注对大鼠脑PGRN表达的影响[J];解剖学研究;2013年01期
9 张景燕;王蓉;赵静姝;姬志娟;赵志炜;盛树力;;APP5肽类似物P165和罗格列酮对SH-SY5Y细胞IRS-1和p-CREB表达的影响[J];首都医科大学学报;2011年04期
10 沈伟,李海林 ,叶勤 ,吴瑞枝 ,陆蓉;阿尔茨海默病、阿尔茨海默病混合型及血管性痴呆患者心理及行为症状的比较[J];健康心理学杂志;2003年06期
相关会议论文 前1条
1 井华;谭梦姗;郁金泰;谭兰;;颗粒蛋白前体参与阿尔茨海默病的作用研究[A];第四届全国痴呆与认知障碍学术研讨会及高级讲授班论文汇编[C];2015年
，本文编号：2204156
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2204156.html
最近更新
教材专著
